Cancer Diagnostics - Global Market Outlook (2017-2023)

August 2017 | 132 pages | ID: CD41A98D0D7EN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Cancer Diagnostics market is expected to grow from $8.54 billion in 2016 to reach $22.41 billion by 2023 with a CAGR of 14.8 %. Increasing incidence of cancer diseases, growing awareness about health care, and recent technological advancements in diagnostic devices are some of the factors propelling the market growth. In addition, favorable government reimbursement policies, increasing investments in research and development activities are some other factors boosting the market growth during the forecast period. On the other hand, high costs of diagnostic devices, strict regulations for new product approvals are the factors limiting the market growth.

Globally, cancer is the most emerging disease in recent times. Cervical, breast, liver, blood, kidney, colorectal, pancreatic, ovarian, melanoma, and lung cancers are types of cancers persisting in humans. Diagnosing at early stage can cure the disease and limit the disease severity. Research institutes have the high adoption rate of cancer diagnostic devices due to heavy funding from government and private institutions.

North America is estimated to be the dominant one among all, due to developed healthcare infrastructure, government initiatives towards public health care that are expected to drive this dominance. Asia Pacific region is predicted to grow at higher CAGR during the forecast period. The growth is attributed to rise in medical tourism market, increase in prevalence of cancer disease in countries such as Japan, China, and India are favoring the Asia Pacific market growth.

Some of the key players in global Cancer Diagnostics market include Abbott Diagnostics, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMérieux, C.R. Bard, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (A Subsidiary of General Electric Company), Hologic,Inc., Illumina, Inc., Koninklijke Philips N.V., Qiagen, Roche Diagnostics, Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc.

Technologies Covered:

• Instrument-Based
• Platform-Based Diagnostics
• Tumor Biomarkers Tests

Applications Covered:

• Cervical Cancer
• Breast Cancer
• Liver Cancer
• Blood Cancer
• Kidney Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Melanoma
• Lung Cancer
• Other Cancers

End Users Covered:

• Cancer Research Institutes
• Diagnostic Laboratories
• Hospital Associated Labs
• Other End Users

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• UK
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• Rest of Asia Pacific
• South America
• Argentina
• Brazil
• Chile
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• UAE
• Qatar
• South Africa
• Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

5.1 Introduction
5.2 Instrument-Based
  5.2.1 Biopsies
    5.2.1.1 Needle Biopsy
    5.2.1.2 Endoscopic Biopsy
    5.2.1.3 Bone Marrow Biopsy
    5.2.1.4 Others
  5.2.2 Liquid Biopsy
  5.2.3 Diagnostic Imaging
    5.2.3.1 Mammography
    5.2.3.2 Ultrasound
    5.2.3.3 Magnetic Resonance Imaging (MRI)
    5.2.3.4 Computed Tomography (CT)
    5.2.3.5 Positron Emission Tomography (PET)
      5.2.3.5.1 Standalone Positron Emission Tomography
      5.2.3.5.2 Hybrid Positron Emission Tomography
5.3 Platform-Based Diagnostics
  5.3.1 Immunohistochemistry (IHC)
  5.3.2 Flow Cytometry
  5.3.3 In Situ Hybridization (ISH)
  5.3.4 Polymerase Chain Reaction (PCR)
  5.3.5 Next-Generation Sequencing (NGS)
  5.3.6 Microarrays
  5.3.7 Other Technologies
5.4 Tumor Biomarkers Tests
  5.4.1 AFP Tests
  5.4.2 CA-19 Tests
  5.4.3 BRCA Tests
  5.4.4 ALK Tests
  5.4.5 CEA Tests
  5.4.6 KRAS Mutation Tests
  5.4.7 HER2 Tests
  5.4.8 EGFR Mutation Tests
  5.4.9 CTC Tests
  5.4.10 PSA Tests
  5.4.11 Other Tumor Biomarkers Tests

6 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION

6.1 Introduction
6.2 Cervical Cancer
6.3 Breast Cancer
6.4 Liver Cancer
6.5 Blood Cancer
6.6 Kidney Cancer
6.7 Colorectal Cancer
6.8 Pancreatic Cancer
6.9 Ovarian Cancer
6.10 Melanoma
6.11 Lung Cancer
6.12 Other Cancers

7 GLOBAL CANCER DIAGNOSTICS MARKET, BY END USER

7.1 Introduction
7.2 Cancer Research Institutes
7.3 Diagnostic Laboratories
7.4 Hospital Associated Labs
7.5 Other End Users

8 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1 Introduction
8.2 North America
  8.2.1 US
  8.2.2 Canada
  8.2.3 Mexico
8.3 Europe
  8.3.1 Germany
  8.3.2 UK
  8.3.3 Italy
  8.3.4 France
  8.3.5 Spain
  8.3.6 Rest of Europe
8.4 Asia Pacific
  8.4.1 Japan
  8.4.2 China
  8.4.3 India
  8.4.4 Australia
  8.4.5 New Zealand
  8.4.6 South Korea
  8.4.7 Rest of Asia Pacific
8.5 South America
  8.5.1 Argentina
  8.5.2 Brazil
  8.5.3 Chile
  8.5.4 Rest of South America
8.6 Middle East & Africa
  8.6.1 Saudi Arabia
  8.6.2 UAE
  8.6.3 Qatar
  8.6.4 South Africa
  8.6.5 Rest of Middle East & Africa

9 KEY DEVELOPMENTS

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 COMPANY PROFILING

10.1 Abbott Diagnostics
10.2 Agilent Technologies, Inc.
10.3 Becton, Dickinson and Company
10.4 bioMérieux
10.5 C.R. Bard, Inc.
10.6 F. Hoffmann-La Roche Ltd.
10.7 GE Healthcare (A Subsidiary of General Electric Company)
10.8 Hologic,Inc.
10.9 Illumina, Inc.
10.10 Koninklijke Philips N.V.
10.11 Qiagen
10.12 Roche Diagnostics
10.13 Siemens Healthcare GmbH
10.14 Thermo Fisher Scientific, Inc.

List Of Tables

LIST OF TABLES

Table 1 Global Cancer Diagnostics Market Outlook, By Region (2014-2023) ($MN)
Table 2 Global Cancer Diagnostics Market Outlook, By Technology (2014-2023) ($MN)
Table 3 Global Cancer Diagnostics Market Outlook, By Instrument-Based (2014-2023) ($MN)
Table 4 Global Cancer Diagnostics Market Outlook, By Biopsies (2014-2023) ($MN)
Table 5 Global Cancer Diagnostics Market Outlook, By Liquid Biopsy (2014-2023) ($MN)
Table 6 Global Cancer Diagnostics Market Outlook, By Diagnostic Imaging (2014-2023) ($MN)
Table 7 Global Cancer Diagnostics Market Outlook, By Platform-Based Diagnostics (2014-2023) ($MN)
Table 8 Global Cancer Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2014-2023) ($MN)
Table 9 Global Cancer Diagnostics Market Outlook, By Flow Cytometry (2014-2023) ($MN)
Table 10 Global Cancer Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2014-2023) ($MN)
Table 11 Global Cancer Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2014-2023) ($MN)
Table 12 Global Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2014-2023) ($MN)
Table 13 Global Cancer Diagnostics Market Outlook, By Microarrays (2014-2023) ($MN)
Table 14 Global Cancer Diagnostics Market Outlook, By Other Technologies (2014-2023) ($MN)
Table 15 Global Cancer Diagnostics Market Outlook, By Tumor Biomarkers Tests (2014-2023) ($MN)
Table 16 Global Cancer Diagnostics Market Outlook, By AFP Tests (2014-2023) ($MN)
Table 17 Global Cancer Diagnostics Market Outlook, By CA-19 Tests (2014-2023) ($MN)
Table 18 Global Cancer Diagnostics Market Outlook, By BRCA Tests (2014-2023) ($MN)
Table 19 Global Cancer Diagnostics Market Outlook, By ALK Tests (2014-2023) ($MN)
Table 20 Global Cancer Diagnostics Market Outlook, By CEA Tests (2014-2023) ($MN)
Table 21 Global Cancer Diagnostics Market Outlook, By KRAS Mutation Tests (2014-2023) ($MN)
Table 22 Global Cancer Diagnostics Market Outlook, By HER2 Tests (2014-2023) ($MN)
Table 23 Global Cancer Diagnostics Market Outlook, By EGFR Mutation Tests (2014-2023) ($MN)
Table 24 Global Cancer Diagnostics Market Outlook, By CTC Tests (2014-2023) ($MN)
Table 25 Global Cancer Diagnostics Market Outlook, By PSA Tests (2014-2023) ($MN)
Table 26 Global Cancer Diagnostics Market Outlook, By Other Tumor Biomarkers Tests (2014-2023) ($MN)
Table 27 Global Cancer Diagnostics Market Outlook, By Application (2014-2023) ($MN)
Table 28 Global Cancer Diagnostics Market Outlook, By Cervical Cancer (2014-2023) ($MN)
Table 29 Global Cancer Diagnostics Market Outlook, By Breast Cancer (2014-2023) ($MN)
Table 30 Global Cancer Diagnostics Market Outlook, By Liver Cancer (2014-2023) ($MN)
Table 31 Global Cancer Diagnostics Market Outlook, By Blood Cancer (2014-2023) ($MN)
Table 32 Global Cancer Diagnostics Market Outlook, By Kidney Cancer (2014-2023) ($MN)
Table 33 Global Cancer Diagnostics Market Outlook, By Colorectal Cancer (2014-2023) ($MN)
Table 34 Global Cancer Diagnostics Market Outlook, By Pancreatic Cancer (2014-2023) ($MN)
Table 35 Global Cancer Diagnostics Market Outlook, By Ovarian Cancer (2014-2023) ($MN)
Table 36 Global Cancer Diagnostics Market Outlook, By Melanoma (2014-2023) ($MN)
Table 37 Global Cancer Diagnostics Market Outlook, By Lung Cancer (2014-2023) ($MN)
Table 38 Global Cancer Diagnostics Market Outlook, By Other Cancers (2014-2023) ($MN)
Table 39 Global Cancer Diagnostics Market Outlook, By End User (2014-2023) ($MN)
Table 40 Global Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2014-2023) ($MN)
Table 41 Global Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2014-2023) ($MN)
Table 42 Global Cancer Diagnostics Market Outlook, By Hospital Associated Labs (2014-2023) ($MN)
Table 43 Global Cancer Diagnostics Market Outlook, By Other End Users (2014-2023) ($MN)
Note: Regional tables are presented in the similar manner as the above